Modeling new immunoregulatory therapeutics as antimicrobial alternatives for treating Clostridium difficile infection

Artificial Intelligence in Medicine

Volumn 78, Issue , 2017, Pages 1-13

  Leber, Andrew ^a   Hontecillas, Raquel ^a   Abedi, Vida ^a   Tubau Juni, Nuria ^a   Zoccoli Rodriguez, Victoria ^a   Stewart, Caroline ^a   Bassaganya Riera, Josep ^a  

^a VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

Author keywords

Clostridium difficile; Gastrointestinal disease modeling; Immunoregulation; In silico clinical trials; LANCL2

Indexed keywords

ANTIBIOTICS; ANTIBODIES; CHEMICAL ACTIVATION; CLOSTRIDIUM; DIFFERENTIAL EQUATIONS; LEARNING ALGORITHMS; LEARNING SYSTEMS; MEDICAL APPLICATIONS; ORDINARY DIFFERENTIAL EQUATIONS; PIPELINES; T-CELLS;

CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; GASTROINTESTINAL DISEASE; IMMUNOREGULATION; LANCL2;

DISEASES;

CLINDAMYCIN; COLISTIN; GENTAMICIN; LANTHIONINE SYNTHETASE C LIKE 2; METRONIDAZOLE; NSC 61610; SYNTHETASE; TOXIN ANTIBODY; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FECAL MICROBIOTA TRANSPLANTATION; IMMUNOREGULATION; INFLAMMATORY CELL; MACHINE LEARNING; MATHEMATICAL MODEL; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION; ANIMAL; CLOSTRIDIUM INFECTION; COMPUTER SIMULATION; MICROFLORA; PEPTOCLOSTRIDIUM DIFFICILE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMPUTER SIMULATION; FECAL MICROBIOTA TRANSPLANTATION; MICROBIOTA;

EID: 85019213779     PISSN: 09333657     EISSN: 18732860     Source Type: Journal    
DOI: 10.1016/j.artmed.2017.05.003     Document Type: Article

References (53)

1. Lessa, F.C., Winston, L.G., McDonald, L.C., Burden of Clostridium difficile infection in the United States. N Engl J Med 372 (2015), 2369–2370.
2. Cornely, O.A., Miller, M.A., Louie, T.J., Crook, D.W., Gorbach, S.L., Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 55:Suppl. 2 (2012), S154–161.
3. Pepin, J., Alary, M.E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40 (2005), 1591–1597.
4. Vindigni, S.M., Surawicz, C.M., C. difficile infection: changing epidemiology and management paradigms. Clin Transl Gastroenterol, 6, 2015, e99.
5. Leber, A., Viladomiu, M., Hontecillas, R., Abedi, V., Philipson, C., Hoops, S., et al. Systems modeling of interactions between mucosal immunity and the gut microbiome during Clostridium difficile infection. PLoS One, 10, 2015, e0134849.
6. Debast, S.B., Bauer, M.P., Kuijper, E.J., European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20:Suppl. 2 (2014), 1–26.
7. Surawicz, C.M., Brandt, L.J., Binion, D.G., Ananthakrishnan, A.N., Curry, S.R., Gilligan, P.H., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108 (2013), 478–498 quiz 499.
8. El Feghaly, R.E., Stauber, J.L., Deych, E., Gonzalez, C., Tarr, P.I., Haslam, D.B., Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis 56 (2013), 1713–1721.
9. Gerding, D.N., Meyer, T., Lee, C., Cohen, S.H., Murthy, U.K., Poirier, A., et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 313 (2015), 1719–1727.
10. Leav, B.A., Blair, B., Leney, M., Knauber, M., Reilly, C., Lowy, I., et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28 (2010), 965–969.
11. van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G., de Vos, W.M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368 (2013), 407–415.
12. Sturla, L., Fresia, C., Guida, L., Bruzzone, S., Scarfi, S., Usai, C., et al. LANCL2 is necessary for abscisic acid binding and signaling in human granulocytes and in rat insulinoma cells. J Biol Chem 284 (2009), 28045–28057.
13. Bruzzone, S., Ameri, P., Briatore, L., Mannino, E., Basile, G., Andraghetti, G., et al. The plant hormone abscisic acid increases in human plasma after hyperglycemia and stimulates glucose consumption by adipocytes and myoblasts. FASEB J 26 (2012), 1251–1260.
14. Zeng, M., van der Donk, W.A., Chen, J., Lanthionine synthetase C-like protein 2 (LanCL2) is a novel regulator of Akt. Mol Biol Cell 25 (2014), 3954–3961.
15. Lu, P., Hontecillas, R., Horne, W.T., Carbo, A., Viladomiu, M., Pedragosa, M., et al. Computational modeling-based discovery of novel classes of anti-inflammatory drugs that target lanthionine synthetase C-like protein 2. PLoS One, 7, 2012, e34643.
16. Carbo, A., Gandour, R.D., Hontecillas, R., Philipson, N., Uren, A., Bassaganya-Riera, J., An N,N-bis(benzimidazolylpicolinoyl)piperazine (BT-11): a novel lanthionine synthetase C-like 2-based therapeutic for inflammatory bowel disease. J Med Chem 59 (2016), 10113–10126.
17. Bissel, P., Boes, K., Hinckley, J., Jortner, B.S., Magnin-Bissel, G., Werre, S.R., et al. Exploratory studies with BT-11: a proposed orally active therapeutic for Crohn's disease. Int J Toxicol 35 (2016), 521–529.
18. Lewis, B.B., Buffie, C.G., Carter, R.A., Leiner, I., Toussaint, N.C., Miller, L.C., et al. Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole. J Infect Dis 212 (2015), 1656–1665.
19. Hutton, M.L., Mackin, K.E., Chakravorty, A., Lyras, D., Small animal models for the study of Clostridium difficile disease pathogenesis. FEMS Microbiol Lett 352 (2014), 140–149.
20. Babcock, G.J., Broering, T.J., Hernandez, H.J., Mandell, R.B., Donahue, K., Boatright, N., et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74 (2006), 6339–6347.
21. Lowy, I., Molrine, D.C., Leav, B.A., Blair, B.M., Baxter, R., Gerding, D.N., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362 (2010), 197–205.
22. Brown, D., Namas, R.A., Almahmoud, K., Zaaqoq, A., Sarkar, J., Barclay, D.A., et al. Trauma in silico: individual-specific mathematical models and virtual clinical populations. Sci Transl Med, 7, 2015 285ra261.
23. Jeena, P.M., Bishai, W.R., Pasipanodya, J.G., Gumbo, T., In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Antimicrob Agents Chemother 55 (2011), 539–545.
24. Kovatchev, B.P., Breton, M., Man, C.D., Cobelli, C., In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol 3 (2009), 44–55.
25. Abedi, V., Lu, P., Hontecillas, R., Verma, M., Vess, G., Philipson, C., et al. Phase III placebo-Controlled, randomized clinical trial with synthetic crohn's disease patients to evaluate treatment response. Arabnia HRaT, Q.N., (eds.) Emerging Trends in Applications and Infrastructure in Computational Biology, Bioinformatics and Systems Biology, 2015, Elsevier, Cambridge, MA, 411–425.
26. Leber, A., Hontecillas, R., Tubau-Juni, N., Bassaganya-Riera, J., Translating nutritional immunology into drug development for inflammatory bowel disease. Curr Opin Gastroenterol 32 (2016), 443–449.
27. Verma, M., Hontecillas, R., Abedi, V., Leber, A., Tubau-Juni, N., Philipson, C., et al. Modeling-enabled systems nutritional immunology. Front Nutr, 3, 2016, 5.
28. Louie, T.J., Miller, M.A., Mullane, K.M., Weiss, K., Lentnek, A., Golan, Y., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364 (2011), 422–431.
29. Kent, E., Hoops, S., Mendes, P., Condor-COPASI: high-throughput computing for biochemical networks. BMC Syst Biol, 6, 2012, 91.
30. Hearst, M.A., Support vector machines. IEEE Intell Syst Appl 13 (1998), 18–21.
31. Lagaris, I.E., Likas, A., Fotiadis, D.I., Artificial neural networks for solving ordinary and partial differential equations. IEEE Trans Neural Netw 9 (1998), 987–1000.
32. Liaw, A., Wiener, M., Classification and regression by randomForest. 2002, R news 2.3, 18–22.
33. Chen, X., Katchar, K., Goldsmith, J.D., Nanthakumar, N., Cheknis, A., Gerding, D.N., et al. A mouse model of Clostridium difficile–associated disease. Gastroenterology 135 (2008), 1984–1992.
34. Viladomiu, M., Hontecillas, R., Pedragosa, M., Carbo, A., Hoops, S., Michalak, P., et al. Modeling the role of peroxisome proliferator-activated receptor gamma and microRNA-146 in mucosal immune responses to Clostridium difficile. PLoS One, 7, 2012, e47525.
35. Shen, B., Ma, J., Wang, J., Biomedical informatics and computational biology for high-throughput data analysis. Sci World J, 2014, 2014, 398181.
36. Leung, E.L., Cao, Z.W., Jiang, Z.H., Zhou, H., Liu, L., Network-based drug discovery by integrating systems biology and computational technologies. Brief Bioinform 14 (2013), 491–505.
37. Kitano, H., Computational systems biology. Nature 420 (2002), 206–210.
38. Jensen, L.J., Bateman, A., The rise and fall of supervised machine learning techniques. Bioinformatics 27 (2011), 3331–3332.
39. Lu, P., Abedi, V., Mei, Y., Hontecillas, R., Hoops, S., Carbo, A., et al. Supervised learning methods in modeling of CD4+ T cell heterogeneity. BioData Min, 8, 2015, 27.
40. Goldberg, E., Amir, I., Zafran, M., Gophna, U., Samra, Z., Pitlik, S., et al. The correlation between Clostridium-difficile infection and human gut concentrations of Bacteroidetes phylum and Clostridial species. Eur J Clin Microbiol Infect Dis 33 (2014), 377–383.
41. Rodriguez, J.M., Murphy, K., Stanton, C., Ross, R.P., Kober, O.I., Juge, N., et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis, 26, 2015, 26050.
42. McKenney, P.T., Pamer, E.G., From hype to hope: the gut microbiota in enteric infectious disease. Cell 163 (2015), 1326–1332.
43. House, T.W., National Action Plan for Combating Antiobiotic-Resistant Bacteria. 2015.
44. Buffie, C.G., Bucci, V., Stein, R.R., McKenney, P.T., Ling, L., Gobourne, A., et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517 (2015), 205–208.
45. Abt, M.C., McKenney, P.T., Pamer, E.G., Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol 14 (2016), 609–620.
46. Voth, D.E., Ballard, J.D., Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18 (2005), 247–263.
47. Cresci, G., Nagy, L.E., Ganapathy, V., Lactobacillus GG and tributyrin supplementation reduce antibiotic-induced intestinal injury. JPEN J Parenter Enteral Nutr 37 (2013), 763–774.
48. Quesada-Gomez, C., Lopez-Urena, D., Chumbler, N., Kroh, H.K., Castro-Pena, C., Rodriguez, C., et al. Analysis of TcdB proteins within the hypervirulent clade 2 reveals an impact of RhoA glucosylation on Clostridium difficile proinflammatory activities. Infect Immun 84 (2016), 856–865.
49. Ng, J., Hirota, S.A., Gross, O., Li, Y., Ulke-Lemee, A., Potentier, M.S., et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 139 (2010), 542–552 552 e541-543.
50. Naaber, P., Mikelsaar, R.H., Salminen, S., Mikelsaar, M., Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection. J Med Microbiol 47 (1998), 591–598.
51. Buffie, C.G., Bucci, V., Stein, R.R., McKenney, P.T., Ling, L., Gobourne, A., et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517 (2014), 205–208.
52. Antharam, V.C., Li, E.C., Ishmael, A., Sharma, A., Mai, V., Rand, K.H., et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol 51 (2013), 2884–2892.
53. Ozaki, E., Kato, H., Kita, H., Karasawa, T., Maegawa, T., Koino, Y., et al. Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. J Med Microbiol 53 (2004), 167–172.